MedTrace Logo

Topical Timolol Gel for the Treatment of Infantile Hemangiomas

NCT02145884 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2017-02-13

No results posted yet for this study

Summary

We plan to conduct a study, to see how safe and effective timolol maleate 0.5% gel-forming solution is for infantile hemangiomas (IH) and the response of hemangiomas to timolol maleate 0.5% . Our hypothesis is that timolol will inhibit and possibly reverse growth of appropriate infantile hemangiomas.

Conditions

  • Hemangioma

Interventions

DRUG

timolol maleate 0.5% gel

Apply timolol gel 1-2 drops twice a day to lesion

Sponsors & Collaborators

  • Valeant Pharmaceuticals

    collaborator INDUSTRY

  • Rady Children's Hospital, San Diego

    lead OTHER

Principal Investigators

  • Sheila F Friedlander, MD · Rady Children's Hospital/ University of California, San Diego

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
7 Days
Max Age
6 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2016-10-31
Completion
2016-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02145884 on ClinicalTrials.gov